0
USD
U.S. (TOLL FREE)
+1 (425) 388-2538
Automative

0
U.S. (TOLL FREE)
+1 (425) 388-2538

Non-Small Cell Lung Cancer - Pipeline Insight, 2019

Published Date: March 2019
|
Report Code: DELV-Pipe-218
Home | Category |Health |Health Conditions
Non Small Cell Lung Cancer Pipeline Insight 2019

Non-Small Cell Lung Cancer - Pipeline Insight, 2019

Code: DELV-Pipe-218
Report
March 2019
90 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

"Non-Small Cell Lung Cancer - Pipeline Insight, 2019” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Small Cell Lung Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Non-Small Cell Lung Cancer
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Non-Small Cell Lung Cancer
The report assesses the active Non-Small Cell Lung Cancer pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Non-Small Cell Lung Cancer
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Non-Small Cell Lung Cancer
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Non-Small Cell Lung Cancer
• The report also covers the dormant and discontinued pipeline projects related to the Non-Small Cell Lung Cancer

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Non-Small Cell Lung Cancer to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Non-Small Cell Lung Cancer therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

1. Report Introduction
2. Non-Small Cell Lung Cancer Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Non-Small Cell Lung Cancer
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

 Table 1: Total Products for Non-Small Cell Lung Cancer
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products

List of Figures

Figure 1: Total Products for Non-Small Cell Lung Cancer
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products

"Non-Small Cell Lung Cancer - Pipeline Insight, 2019” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Small Cell Lung Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Non-Small Cell Lung Cancer
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Non-Small Cell Lung Cancer
The report assesses the active Non-Small Cell Lung Cancer pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Non-Small Cell Lung Cancer
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Non-Small Cell Lung Cancer
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Non-Small Cell Lung Cancer
• The report also covers the dormant and discontinued pipeline projects related to the Non-Small Cell Lung Cancer

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Non-Small Cell Lung Cancer to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Non-Small Cell Lung Cancer therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Read More

1. Report Introduction
2. Non-Small Cell Lung Cancer Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Non-Small Cell Lung Cancer
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Read More

List of Tables

 Table 1: Total Products for Non-Small Cell Lung Cancer
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products

List of Figures

Figure 1: Total Products for Non-Small Cell Lung Cancer
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$2000
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$4000
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$6000
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)

RELATED REPORTS

Global Orthopedic Trauma Fixation Devices Market Professional Survey Report 2019
Global Orthopedic Trauma Fixation Devices Market Professional Survey Report 2019

Global Orthopedic Trauma Fixation Devices Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-17W573
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Nasal Cannulas Market Professional Survey Report 2019
Global Nasal Cannulas Market Professional Survey Report 2019

Global Nasal Cannulas Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-20W326
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019
Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019

Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-10H571
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Haemophilus Influenzae Type B Vaccine Market Insights Forecast to 2025
Global Haemophilus Influenzae Type B Vaccine Market Insights Forecast to 2025

Global Haemophilus Influenzae Type B Vaccine Market Insights, Forecast to 2025

120 Pages
Type: Report
Code: QYRE-Auto-28R309
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

0 Items
X
No items in the cart.
$0.0